BackAytu BioPharma Overview

Aytu BioPharma Receivables

Track Aytu BioPharma's receivables ($24M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Receivables
$24.49M
↓ 31.64% YoYΔ $-11.34M vs prior year quarter

Peer trimmed avg / median

Loading

Aytu BioPharma Receivables History

Loading

Aytu BioPharma vs. peers: Receivables Comparison

Loading

Aytu BioPharma Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Aytu BioPharma (AYTU) FAQ

Aytu BioPharma (AYTU) currently reports a receivables of $24M as of March 2026. That compares with $36M in the prior-year period — down 31.6% year over year. Use the charts on this page to explore Aytu BioPharma's receivables history and peer comparisons.

Aytu BioPharma's receivables decreased from $36M to $24M — a 31.6% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Aytu BioPharma reported $24M in receivables as of March 2026. That compares with $36M in the prior-year period — down 31.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $24M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Aytu BioPharma, and consider following AYTU for alerts when major investors trade the stock.

Aytu BioPharma is classified in the Healthcare sector. On receivables, it currently shows $24M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing AYTU with unrelated industries.